Clinical Trial Update: Antitumoral Activity and Safety of AEZS-108 in Women With LHRH Receptor Positive Gynecological Tumors [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating antitumor activity and safety of AEZS-108 in LHRH receptor–positive gynecological tumors (ovarian and endometrial cancers) completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Endometrial Cancer
• Ovarian Cancer

Drugs mentioned

• AEZS-108 (zoptarelin doxorubicin)

Snippet

Sponsor: AEterna Zentaris | Conditions: Ovarian Cancer, Endometrial Cancer | Phase 2 | Status: COMPLETED